1Goldschlager N,Epstein AE,Naccarelli G,et al.Practical guidelines for clinicians who treat patients with amiodarone.Practice Guidelines Subcommittee,North American Society of Pacing and Electrophysiology[J].Arch Intern Med,2000,160(12):1741-1748.
4Zugck C,Kruger C,Durr S,et al.Is the6-minure walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy[J].Eur Heart J,2000,21(7):540-549.
5王海燕.肾脏病学[M].3版.北京:人民卫生出版社,2008:1815-1816.
6Ujhelyi MR,Klamerus KJ,Vadiei K,et al.Disposition of intravenous amiodarone in subjects with normal and impaired renal function[J].J Clin Pharmacol,1996,36(2):122-130.
5Stenvinkel P,Ketteler M,Johnson RJ,et al.IL-10,IL-6,and TNF-alpha:cenlral factors in the altered cytokine network of uremiathe good.the bad,and the ugly[J].Kidney Int,2005,67(4):1216-1233.
7Kumagai K,Nakashima H.The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model[J].Cardiovasc Res,2007,74(1):75-84.
8Porter KE,Turner NA,O'Regan DJ,et al.Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA[J].Cardiovasc Res,2004,61(4):745-755.
9Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Europ Heart J,2001,22:1852-1923.
